Guardian Partners’s AbCellera Biologics ABCL Stock Holding History

Guardian Partners’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.68M	Sell	595,998 -1,190,417	-67%	-$5.82M	0.42%	54
2026 Q1	$6.25M	Buy	1,786,415 +1	+0%	+$4	0.52%	51
2025 Q4	$5.82M	Hold	1,786,414	–	–	0.47%	55
2025 Q3	$10.6M	Hold	1,786,414	–	–	0.9%	38
2025 Q2	$7.54M	Hold	1,786,414	–	–	0.68%	51
2025 Q1	$4.52M	Hold	1,786,414	–	–	0.47%	65
2024 Q4	$5.41M	Buy	+1,786,414	New	+$4.97M	0.55%	57

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Guardian Partners's ABCL Position: Q2 2026 in Review

Guardian Partners reduced its AbCellera Biologics (ABCL) stake by 67% in Q2 2026, selling an estimated $5.82M and leaving 595,998 shares worth $4.68M. The position accounts for 0.42% of the portfolio, ranked #54.

Guardian Partners first reported a position in ABCL in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.6M in Q3 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Guardian Partners held 595,998 shares of AbCellera Biologics worth $4.68M as of Q2 2026.
Guardian Partners sold 1,190,417 AbCellera Biologics shares in Q2 2026, an estimated $5.82M.
AbCellera Biologics made up 0.42% of Guardian Partners's portfolio in Q2 2026, its #54 holding.
Guardian Partners first reported a position in AbCellera Biologics in Q4 2024 and has held it in 7 quarters since.
Guardian Partners's AbCellera Biologics position peaked at $10.6M in Q3 2025.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Guardian Partners's 13F filing for Q2 2026, filed 29 Jul 2026.